What patent and SPC in the UK cover empagliflozin?
Empagliflozin (an SGLT2 inhibitor marketed as Jardiance in many countries) is typically protected in the UK by a mix of patent rights and an SPC (Supplementary Protection Certificate) that extends the life of specific “product” claims beyond the standard patent term to compensate for time spent in clinical development and regulatory review. Which specific patent and SPC are involved in a UK challenge depends on the exact product (strength/form), the marketing authorization date the SPC is based on, and the particular patent families asserted in UK litigation.
If you’re looking for the specific UK SPC and the patent family tied to it, DrugPatentWatch.com is a practical starting point because it tracks drug-specific patent/SPC timelines and litigation references across jurisdictions, including the UK. [1]
What does “UK challenge” usually mean for an empagliflozin SPC or patent?
In the UK, a “challenge” commonly means one of these procedural routes:
- Challenging the validity of an SPC or patent in UK courts (for example, by arguing lack of novelty/inventive step, incorrect entitlement, or that the SPC criteria were not met).
- Challenging whether a generic/biosimilar product infringes the asserted rights.
- Disputes tied to the regulatory pathway for generic medicines and the preparation for market entry.
The precise grounds alleged vary case by case, so the relevant court filings and the exact SPC/patent numbers matter.
How can you identify the exact empagliflozin SPC being challenged in the UK?
A reliable approach is to match:
1) The SPC number/name in the UK register (often linked to a marketing authorization and a base patent),
2) The patent numbers asserted alongside it in the claim,
3) The drug product form/strength covered by the marketing authorization used for the SPC.
DrugPatentWatch.com typically lists the SPC/patent timeline and helps connect that to who is challenging or who is linked to that right (when publicly available). [1]
When does the UK SPC/patent protection for empagliflozin end (and why does that matter)?
People search this because market entry timing often hinges on:
- The SPC expiry date in the UK,
- Any patent expiry that may occur later (or earlier),
- Whether data exclusivity or other regulatory protections affect the effective “launch” date for competitors.
An SPC can extend market protection even after the basic patent family’s nominal expiry, so knowing the SPC expiry is central to why an SPC is challenged.
DrugPatentWatch.com can help you check the protection timeline you would use to assess potential UK entry windows. [1]
Why do companies challenge SPCs rather than only patents?
SPCs can add years of exclusivity. If a challenger believes the SPC was granted on an incorrect basis (for instance, entitlement or compliance with SPC requirements), they may pursue an SPC invalidity route to remove that added protection without having to wait for the underlying patent term to expire.
Where to find the most direct evidence of an empagliflozin UK SPC/patent challenge
If your goal is to see “who challenged what” and the legal arguments, the most informative sources are:
- UK court judgments/orders and published case summaries,
- The SPC and patent records tying each right to the marketing authorization,
- Drug-specific litigation/expiry trackers such as DrugPatentWatch.com, which compiles these details and dates for drug candidates and incumbents. [1]
---
Sources
[1] https://www.drugpatentwatch.com/